BCAC media release, 28 July 2019
Breast Cancer Aotearoa Coalition (BCAC) welcomes the announcement that if elected National would set up an independent cancer agency to ensure every New Zealander gets high-quality cancer care and to eliminate post code inequities.
UK medicines assessor NICE (National Institute for Health and Care Excellence) has just recommended another combination of drugs for women with advanced hormone-receptor-positive breast cancer. Ribociclib is one of three drugs in the CDK 4/6 inhibitor class, which can extend and improve the lives of women with this type of breast cancer.
Three Cambridge women are using their breast cancer journeys to bring support and reassurance to others.
Come join us! The Busting with Life Dragon Boat Team
Have you or someone you know had breast cancer and want to try something new?
Come and give dragon boating a go!
It's fun, great for fitness and proven to be beneficial for breast cancer survivors. Become part of a team of women who participate in this great sport while having a lot of fun!
Progress continues to be made through world-leading research to identify which treatments will work best for different sub-types of breast cancer.
Breast Cancer Aotearoa Coalition (BCAC) is 100% behind Blair Vining’s petition to Parliament calling for a national cancer agency to address New Zealand’s cancer death rates.
Malaghan Institute media release
In brilliant news, it has been discovered that adding ribociclib to first-line endocrine therapy significantly improves both progression free and overall survival (PFS and OS) for premenopausal women with advanced breast cancer.
The Waikato Breast Cancer Research Trust (WBCRT) is seeking participants with moderately severe treatment-resistant lymphoedema for this research. Is lymphoedema of your arm an ongoing problem for you? Have you undergone at least three months of lymphoedema therapy?
Key findings announced at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago include breakthroughs in the treatment of breast cancer and research. In a series of articles including this one, we outline some of the exciting developments reported.
